Stockreport

Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Contro...

Pieris Pharmaceuticals, Inc.  (PIRS) 
NASDAQ:AMEX Investor Relations: ir.pieris.com
PDF WAYNE, Pa., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializi [Read more]